PhD Scientific Days 2024

Poster Session T - Cardiovascular Medicine and Research 3.

Thymic Modulation of Immune Checkpoint Inhibitor-Induced Cardiotoxicity: New Perspectives In Immunotherapy

Előadó neve

Kocsis, Márton

Neptun code

dx26uf

Előadó munkahelye

Farmakológiai és Farmakoterápiás Intézet

Előadó telefonszáma

06308252435

Előadó e-mail címe

kocsis.marton@semmelweis.hu

Az előadás címe

Thymic Modulation of Immune Checkpoint Inhibitor-Induced Cardiotoxicity: New Perspectives In Immunotherapy

Szerző(k) neve és munkahelye

Kocsis Márton¹, Dr. Varga Zoltán¹

1: SE Farmakológiai és Farmakoterápiás Intézet

Bemutatás módja

Poszter

Szekció

Poster Session T - Cardiovascular Medicine and Research 3.

Language of the presentation

English

Preferred session

Cardiovascular Medicine and Research

Összefoglaló szövege

Immune checkpoint inhibitors (ICI) are monoclonal antibodies that enhance the anti-tumor activity of the immune system. However, this therapy could lead to immune overactivation, resulting in severe side effects associated with high mortality rates. Previously, we demonstrated that ICI increases the expression of inflammatory genes in the thymus, and furthermore in clinical studies, ICI therapy for thymoma treatment caused severe cardiotoxicity. Based on these findings, we hypothesized that thymus activity could play an important role in ICI-induced autoimmune side effects.
The main aim of our study was to investigate the correlation between thymus activity and the pathophysiological processes of immune-mediated cardiotoxic and systemic side effects during ICI therapy using a preclinical mouse model. Since the thymus gradually atrophies and thymic activity decreases with age, we examined the side effects of ICIs in two differently aged groups, plus artificially degraded the thymus with pharmacological treatment in young animals.
Based on our results, thymic immune response plays a central role in ICI-induced cardiotoxicity in mice. In aged animals undergoing ICI treatment and combined immunotherapy with parallel pharmacologically induced involution of the thymus significantly reduced side effects, indicating that the immune response following ICI treatment varies depending on thymic activity.
Thus, modulation of thymus activity may serve as a therapeutic target in reducing immune-mediated side effects and also monitoring the morphology and activity may be an important factor in predicting the severity of side effects and identifying high-risk patients.
With Resolve’s Spatial Cartography, by screening the thymus of ICI treated animals, we could identify targets that could predict the prevalence and severity of ICI induced immune related adverse events. In further experiments our final goal is to be able to detect these targets in the blood of patients before ICI treatment so we could use them as predictive biomarkers for possible immune related adverse events.

University

Semmelweis University

Supervisor

Dr. Varga Zoltán

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

8118

Start

16:35

End

16:38